What is Citigroup's price target for MRSN?

Citigroup's latest stated price target for Mersana Therapeutics Inc. (MRSN) is $5, from its action on Nov 15, 2024.

What is Citigroup's rating on MRSN?

Citigroup rates MRSN Buy, a bullish rating, as of Nov 15, 2024.

When did Citigroup last change its view on MRSN?

On Nov 15, 2024, Citigroup resumes coverage at Buy, price target $5.

Citigroup MRSN price target and rating history

Mersana Therapeutics Inc. (MRSN) · Health Care

Citigroup rates Mersana Therapeutics Inc. (MRSN) Buy with a $5 price target, as of its latest action on Nov 15, 2024. It has published 4 rating actions on MRSN since January 2023, including 1 upgrade and 1 downgrade.

Current rating: Buy
Price target: $5
Median target, all firms: Too few
Actions on MRSN: 4

Citigroup price target on MRSN

Citigroup price target on MRSN, each point a stated target, January 2023 to November 2024. Targets before December 2023 (divided by 12) are adjusted for a stock split, going by the prior target Citigroup restated.

Every Citigroup rating on MRSN

Nov 15, 2024
ResumeCitigroup resumes coverage at Buy, price target $5
Dec 4, 2023
UpgradeCitigroup upgrades to Buy from Neutral, price target $1 to $5
Jul 27, 2023
DowngradeCitigroup downgrades to Neutral from Buy
Jan 20, 2023
InitiateCitigroup starts coverage at Buy, price target $12

Questions about Citigroup and MRSN

What is Citigroup's price target for MRSN?: Citigroup's latest stated price target for Mersana Therapeutics Inc. (MRSN) is $5, from its action on Nov 15, 2024.
What is Citigroup's rating on MRSN?: Citigroup rates MRSN Buy, a bullish rating, as of Nov 15, 2024.
When did Citigroup last change its view on MRSN?: On Nov 15, 2024, Citigroup resumes coverage at Buy, price target $5.

More MRSN rating histories

All Citigroup ratings MRSN news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.